Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS
BanuAnlar, Hacettepe University, Dept of Pediatric Neurology, Ankara, Turkey 06100banlar@hacettepe.edu.tr
Submitted November 07, 2006
The study of Aydin et al [1] adds to current data on the pathogenesis of subacute sclerosing panencephalitis (SSPE) and supports
the role of neuronal loss in the progression of neurological dysfunction.
The authors also observed increasing myoinositol (mI) until stage 3 of the
disease, which they related to astrogliosis. However, patients progressing
to stage 4 had lower concentrations of mI.
Because a reduction in
astrogliosis is unexpected in late stages of SSPE, I think this metabolite
might have been affected by inosiplex treatment as previously reported by Kato et al. [2] All patients in the study were under inosiplex treatment, but
compliance frequently diminishes when patients progress to more advanced
stages of the disease despite treatment. The role of medication should be
considered in interpreting MRS results.
References
1.Aydin K, Tatli B, Ozkan M, et al. Quantification of neurometabolites in
subacute sclerosing panencephalitis by 1H-MRS.Neurology 2006;67:911-913.
2.Kato Z, Asano T, Kondo N. Inosiplex Affects the Spectra of Proton
Magnetic Resonance Spectroscopy in Subacute Sclerosing Panencephalitis.
Journal of Child Neurology 2006;21:177-178.
Disclosure: The author reports no conflicts of interest.
The study of Aydin et al [1] adds to current data on the pathogenesis of subacute sclerosing panencephalitis (SSPE) and supports the role of neuronal loss in the progression of neurological dysfunction. The authors also observed increasing myoinositol (mI) until stage 3 of the disease, which they related to astrogliosis. However, patients progressing to stage 4 had lower concentrations of mI.
Because a reduction in astrogliosis is unexpected in late stages of SSPE, I think this metabolite might have been affected by inosiplex treatment as previously reported by Kato et al. [2] All patients in the study were under inosiplex treatment, but compliance frequently diminishes when patients progress to more advanced stages of the disease despite treatment. The role of medication should be considered in interpreting MRS results.
References
1.Aydin K, Tatli B, Ozkan M, et al. Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS.Neurology 2006;67:911-913.
2.Kato Z, Asano T, Kondo N. Inosiplex Affects the Spectra of Proton Magnetic Resonance Spectroscopy in Subacute Sclerosing Panencephalitis. Journal of Child Neurology 2006;21:177-178.
Disclosure: The author reports no conflicts of interest.